Overview
CLBT market data
Price History
CLBT price chart
Valuation & Profitability
- P/E (TTM)
- 37.49 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.31 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 14.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.58 – $19.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.7B · P/B 8.91 · P/S 5.43.
Company News
Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15Benzinga · Aug 14, 2026, 8:08 PM
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16Benzinga · Aug 14, 2026, 4:19 PM
DA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15Benzinga · Aug 14, 2026, 1:57 PM
Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5Benzinga · Aug 14, 2026, 11:21 AM
Cellebrite Shares Plunge Thursday: What's Driving the Move?Benzinga · Aug 13, 2026, 4:52 PM
Gold Down 2%; Cisco Shares Tumble After Q4 ResultsBenzinga · Aug 13, 2026, 4:12 PM
Full Transcript: Cellebrite DI Q2 2026 Earnings CallBenzinga · Aug 13, 2026, 2:03 PM
Dow Gains Over 100 Points; Producer Prices Unchanged In JulyBenzinga · Aug 13, 2026, 1:44 PM
Cellebrite DI shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 sales guidance below estimates. Also, the company cut its FY26 sales guidance below estimates.Benzinga · Aug 13, 2026, 11:33 AM
Cellebrite DI Lowers FY2026 Sales Guidance from $565.000M-$571.000M to $555.000M-$561.000M vs $568.048M EstBenzinga · Aug 13, 2026, 11:23 AM